2019
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Research 2019, 21: 78. PMID: 31277699, PMCID: PMC6612080, DOI: 10.1186/s13058-019-1154-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkersBreast NeoplasmsClass I Phosphatidylinositol 3-KinasesDrug MonitoringFemaleHeterocyclic Compounds, 3-RingHigh-Throughput Nucleotide SequencingHumansImmunohistochemistryMiddle AgedMutationNeoplasm MetastasisNeoplasm StagingProtein Kinase InhibitorsProto-Oncogene Proteins c-aktTreatment OutcomeConceptsObjective response ratePeripheral blood mononuclear cellsPlatelet-rich plasmaAdvanced breast cancerPhase II trialPre-treatment biopsiesBreast cancerAKT inhibitor MKAKT1 mutationsPTEN lossII trialPIK3CA mutationsPIK3CA/AKT1 mutationsAdvanced breast cancer patientsInhibitor MKTriple-negative breast cancerMethodsThe primary endpointPIK3CA/AKT1Common adverse eventsPre-treated patientsProgression-free survivalResultsTwenty-seven patientsBreast cancer patientsBlood mononuclear cellsPTEN mutations
2012
E6. Can an international consensus meeting change the future of advanced breast cancer patients? Highlights from ABC1 Consensus Meeting
Cardoso F, Winer E, Norton L, Gomis R, Krop I, Harbeck N, Costa A. E6. Can an international consensus meeting change the future of advanced breast cancer patients? Highlights from ABC1 Consensus Meeting. European Journal Of Cancer 2012, 48: s13-s14. DOI: 10.1016/s0959-8049(12)70057-6.Peer-Reviewed Original ResearchConsensus meetingAdvanced breast cancer patientsBreast cancer patientsInternational Consensus MeetingCancer patientsPatients
2008
VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy
Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy. Clinical Cancer Research 2008, 14: 7871-7877. PMID: 19047116, DOI: 10.1158/1078-0432.ccr-08-0593.Peer-Reviewed Original ResearchConceptsAdvanced breast cancer patientsRefractory breast cancerBreast cancer patientsBreast cancerPlasma VEGFCancer patientsTreatment outcomesSide effectsAnti-vascular endothelial growth factor therapyAdequate end-organ functionEndothelial growth factor therapyImportant new treatment modalityTumor hormone receptor statusMonoclonal anti-VEGF antibodyPrior chemotherapy regimensEnd-organ functionHormone receptor statusAnti-VEGF therapyMetastatic breast cancerGrowth factor therapyNew treatment modalitiesWarrants further evaluationAnti-VEGF antibodyBaseline VEGFEligible patients
2007
Care in the Months before Death and Hospice Enrollment Among Older Women with Advanced Breast Cancer
Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ. Care in the Months before Death and Hospice Enrollment Among Older Women with Advanced Breast Cancer. Journal Of General Internal Medicine 2007, 23: 11-18. PMID: 17939006, PMCID: PMC2173914, DOI: 10.1007/s11606-007-0422-y.Peer-Reviewed Original ResearchConceptsTypes of physiciansAdvanced breast cancerWeeks of deathHospice useOutpatient visitsCancer specialistsBreast cancerOlder womenStage III/IV breast cancerEnd Results-Medicare databaseAdvanced breast cancer patientsBreast cancer patientsPrimary care providersPopulation-based sampleTiming of enrollmentHospice referralPatient characteristicsHospice enrollmentHospitalized patientsCancer careCancer patientsAdjusted ratesCare providersHospitalizationPatients
1999
Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group.
Goss PE, Winer EP, Tannock IF, Schwartz on behalf of the North American Vorozole Study Grou L. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. Journal Of Clinical Oncology 1999, 17: 52-63. PMID: 10458218, DOI: 10.1200/jco.1999.17.1.52.Peer-Reviewed Original ResearchConceptsPostmenopausal advanced breast cancer patientsAdvanced breast cancer patientsPhase III trialsBreast cancer patientsMegestrol acetateIII trialsCancer patientsTreatment groupsRandomized phase III trialUpper respiratory tract infectionSecond-line therapyAdvanced breast cancerDiscontinuation of treatmentRespiratory tract infectionsAromatase inhibitor vorozoleQuality of lifeMore dyspneaPostmenopausal womenAdverse eventsHot flushesMedian durationObjective responsePartial responseTamoxifen treatmentTract infections
1995
Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer.
Winer EP, Chu L, Spicer DV. Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. Seminars In Oncology 1995, 22: 72-8; discussion 78-9. PMID: 7740337.Peer-Reviewed Original ResearchConceptsAdvanced breast cancerOral vinorelbineBreast cancerIntravenous administrationResponse rateMulticenter phase II trialAdvanced breast cancer patientsPhase II trialHigh first-pass effectBreast cancer patientsFirst-pass effectPharmacokinetics of vinorelbineII trialCancer patientsClinical investigationVinorelbineHigh clearance rateSoft gelatin capsulesClearance ratePatientsCancerPharmacokinetic studyLow bioavailabilityAdministrationGelatin capsules